8-K: Trevi Therapeutics Aligns with FDA on Phase 3, Reports Strong Cash Position

Trevi Therapeutics announced positive financial results for Q4 and full-year 2025, secured FDA alignment for its Haduvio Phase 3 program, and plans to initiate multiple clinical trials in 2026.

Summary

• Trevi Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2025.
• The company gained overall alignment with the FDA on its Phase 3 program for idiopathic pulmonary fibrosis (IPF)-related chronic cough following an End-of-Phase 2 meeting.
• Plans include two pivotal Phase 3 clinical trials for IPF-related chronic cough, with the first initiating in Q2 2026 and the second in H2 2026.
• A Phase 2b clinical trial for refractory chronic cough (RCC) is on track to initiate in Q2 2026.
• An adaptive design Phase 2b trial for non-IPF interstitial lung disease (non-IPF ILD)-related chronic cough is planned for H2 2026.
• The company ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway into 2028.
• Net loss for Q4 2025 decreased to $8.3 million compared to $11.4 million in Q4 2024.
• Net loss for the full year 2025 decreased to $42.8 million compared to $47.9 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, primarily driven by the critical FDA alignment for the Phase 3 program, strong cash position, and improved financial performance, significantly de-risking the company's development path.

Positives

• Gained overall alignment with the FDA on the Phase 3 program for IPF-related chronic cough, a significant de-risking event for the development pathway.
• Ended 2025 with a strong cash position of $188.3 million in cash, cash equivalents, and marketable securities, extending the expected cash runway into 2028.
• Net loss significantly decreased in Q4 2025 to $8.3 million from $11.4 million in Q4 2024.
• Full year 2025 net loss also decreased to $42.8 million from $47.9 million in 2024.
• Research and development (R&D) expenses decreased in Q4 2025 to $6.2 million from $9.3 million in Q4 2024, and for the full year 2025 to $33.5 million from $39.4 million in 2024, reflecting completion of earlier phase trials.
• Other income, net, increased in Q4 2025 to $1.9 million from $0.8 million in Q4 2024, and for the full year 2025 to $6.5 million from $3.6 million in 2024, due to higher invested balances.
• Positive Phase 2 data across chronic cough programs provided a strong foundation for growth.
• Key Phase 2b CORAL trial results for IPF-related chronic cough were published in the Journal of the American Medical Association (JAMA) in January 2026, adding scientific validation.

Negatives

• General and administrative (G&A) expenses increased in Q4 2025 to $4.0 million from $2.9 million in Q4 2024, and for the full year 2025 to $15.9 million from $12.1 million in 2024, primarily due to increased professional fees and personnel-related expenses.
• The company continues to operate at a net loss, reporting $8.3 million for Q4 2025 and $42.8 million for the full year 2025, as is typical for a clinical-stage biopharmaceutical company.

Risks

• Uncertainties regarding the success, cost, and timing of product candidate development activities and clinical trials.
• The risk that positive data from a clinical trial (e.g., Phase 2) may not necessarily be predictive of the results of later clinical trials (e.g., Phase 3) in the same or a different indication.
• Uncertainties regarding the company's ability to execute on its strategy.
• Uncertainties with respect to regulatory authorities' views as to the data from clinical trials and next steps in the development path for Haduvio in the United States and foreign countries.
• Uncertainties inherent in estimating the company's cash runway, future expenses, and other financial results, including the ability to fund future operations and clinical trials.
• The company is subject to other risks and uncertainties set forth in its quarterly report on Form 10-Q for the quarter ended September 30, 2025, and in subsequent SEC filings.

Future Outlook

Trevi Therapeutics is well-positioned to execute on its clinical programs, with plans to initiate two pivotal Phase 3 trials for IPF-related chronic cough and Phase 2b trials for refractory chronic cough and non-IPF ILD-related chronic cough in 2026. The company expects to conduct remaining Phase 1 clinical studies to support a New Drug Application (NDA) submission for Haduvio.

Management Comments

• "Our progress in 2025 marked a major inflection point for Trevis growth trajectory, driven by positive Phase 2 data across our chronic cough programs."
• "These results provide a strong foundation as we pursue our goal of becoming a leader in treating chronic cough."
• "Weve carried this momentum into 2026 as we gained overall alignment with the FDA during our End-of-Phase 2 meeting for patients with IPF-related chronic cough."
• "We are now focused on initiating the first of our two pivotal Phase 3 IPF-related chronic cough trials, as well as our Phase 2b RCC trial in the second quarter of this year."
• "Looking ahead, Trevi is well positioned to execute on its clinical programs and help address the high unmet need for patients who are burdened by chronic cough in our target indications, where there are no FDA-approved therapies."

Industry Context

StockSavvy.ai notes that Trevi Therapeutics operates in a high unmet medical need area, as there are currently no FDA-approved therapies for chronic cough in patients with IPF, non-IPF ILD, or refractory chronic cough. The company's investigational therapy, Haduvio, is highlighted as the first and only to show statistically significant reduction in cough frequency across both IPF chronic cough and RCC in clinical trials, positioning it as a potential first-in-class treatment in a market affecting millions of U.S. patients. The progression to Phase 3 with FDA alignment is a critical step in a competitive biopharmaceutical landscape.

Comparison to Industry Standards

• The alignment with the FDA on a Phase 3 program for a novel therapy like Haduvio is a significant de-risking event, comparable to milestones achieved by other clinical-stage biopharmaceutical companies advancing therapies for conditions with high unmet needs, such as those in rare disease or oncology.
• The publication of Phase 2b CORAL trial results in JAMA indicates a high level of scientific rigor and peer validation, a standard often seen with leading clinical data in the pharmaceutical industry.
• The cash runway into 2028, with $188.3 million in cash, cash equivalents, and marketable securities, provides a strong financial position for a clinical-stage company, exceeding the typical 12-18 month runway often observed in smaller biotechs, and is comparable to well-funded peers like Vertex Pharmaceuticals in its early development stages for cystic fibrosis treatments or Regeneron Pharmaceuticals during its early pipeline expansion.
• The focus on chronic cough in IPF, non-IPF ILD, and RCC addresses patient populations with no FDA-approved therapies, similar to the strategic focus of companies like FibroGen in fibrosis or Intercept Pharmaceuticals in liver diseases, targeting significant market opportunities with high unmet needs.

Stakeholder Impact

• Shareholders: Positive impact due to FDA alignment de-risking the Haduvio development, strong cash runway, and improved financial results, potentially increasing confidence in future value.
• Patients: Potential positive impact as the company progresses Haduvio, a promising therapy, towards approval for conditions with high unmet needs and no FDA-approved treatments.
• Employees: Continued stability and potential growth opportunities as the company advances its clinical programs.
• Regulatory Authorities: The FDA's alignment on the Phase 3 program indicates a clear path forward for regulatory review.

Next Steps

• Initiate the first pivotal Phase 3 clinical trial for IPF-related chronic cough in Q2 2026.
• Initiate a Phase 2b clinical trial for refractory chronic cough (RCC) in Q2 2026.
• Initiate the second pivotal Phase 3 clinical trial for IPF-related chronic cough in H2 2026.
• Initiate an adaptive design Phase 2b trial for non-IPF ILD-related chronic cough in H2 2026.
• Conduct remaining Phase 1 clinical studies to support a New Drug Application (NDA) submission.
• Host an Investor and Analyst Day on May 7, 2026, in New York City.

Key Dates

Recommendation

The FDA alignment on the Phase 3 program for IPF-related chronic cough is a major de-risking event, providing a clear regulatory pathway for Haduvio, which has already shown positive Phase 2 data and addresses a significant unmet medical need. The strong cash position of $188.3 million, extending the runway into 2028, provides ample funding for the upcoming pivotal trials without immediate dilution concerns. The improved financial performance, with reduced net losses and R&D expenses, further strengthens the company's operational efficiency. Given the significant market opportunity for chronic cough treatments and the advanced stage of Haduvio's development, these updates collectively present a compelling investment case for a strong buy.

Keywords

Trevi Therapeutics, TRVI, Haduvio, nalbuphine ER, chronic cough, IPF, idiopathic pulmonary fibrosis, refractory chronic cough, non-IPF ILD, interstitial lung disease, Phase 3 clinical trials, FDA alignment, biopharmaceutical, clinical-stage, financial results, cash runway, R&D expenses, net loss